This site is intended to use by healthcare professionals only

Bacteria friends
of your health


  • The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment

    The probiotic compound VSL#3 has an extensive impact on mucosal, peripheral, and systemic innate as well as adaptive immunity, exerting beneficial anti-inflammatory effects in intestinal as well as systemic compartments. Hence VSL#3 might be considered a therapeutic immunomodulatory tool following a

  • The World of Microbiota

    Prof. Antonio Gasbarrini is Professor at Università Cattolica del Sacro Cuore and Director of the Specialization school of Gastroenterology and Digestive Endoscopy of Policlinico Gemelli, in Rome. Discussing on the world of Microbiota and Gut microbiota we asked him to explaine us what is a Micr

  • VSL#3 participates at XVIII Convegno Nazionale ANSISA

    VSL#3 will take part in XVIII Convegno Nazionale ANSISA host to NH Hotel in Assago Milano. On November 17th -18th ANSISA 's national congress (National Association of specialists in Nutritional science) will be focus on Clinical nutrition. As part of the plenary session on Elements of integrat

  • VSL#3 Lunch Meeting in Rome

    Microbiota and probiotics: what's their role for organism? During the last Lunch Meeting in Rome we asked our experts to give us more details about the importance of Gut Microbiota, the contribution of probiotics in health and its market. If we consider both US and Europe, the probiotics market valu

  • VSL#3 with Ferring at the 25th UEG Week

    VSL#3 with Ferring partecipated to the 25th UEG Week (United European Gastroenterology) in Barcelona where a world class faculty gathered to present newest research as well as state-of-the art clinical practice. The 25th UEG Week Congress was concluded on November 1st and Actial Farmaceutica’s

  • 9th PROBIOTICS, PREBIOTICS & NEW FOODS: VSL#3 Symoposium on Sept 11st

    From 10-12 September 2017 VLS#3 Pharma and Ferring will be in Rome to take part in 9th PROBIOTICS, PREBIOTICS & NEW FOODS NUTRACEUTICALS AND BOTANICALS Conference, that will be held at Università Urbaniana. 609

  • VSL#3 partecipates to LAB12, International Symposium on Lacid Bacteria

    From 27th to 31st August, VSL#3 will partecipate to The 12th Symposium on Lactic Acid Bacteria that will be held in the Congress Centre “Hotel Zuiderduin”, in Egmond aan Zee, Netherlands. 612

  • VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis

    Scientific article "The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis" published by Journal of Histochemistry & Cytochemistry reports the analitic results of VSL#3's effects on macrophages in acute trinitrobenzene sulfo

  • VSL#3 in ESPCG’s guideline

    "Probiotics in the management of lower GI symptoms in clinical practice" is the Practical reference guide developed by ESPCG (European Society for Primary Care Gastroenterology) the European Association of Academic General Practitioners with big interest in GI. The Guidelines has been written with t

  • VSL#3: efficacy in Pouchitis

    Pouchitis is a common complication in patients undergoing restorative proctocolectomy for ulcerative colitis. A systematic review made by The Rabin Medical Center, has supported the use of probiotics and prebiotics in pouchitis patients, aiming to clarify the place of these treatments in current the